covid19med

Why a new report is so troubling

Are vaccines needed if you already had COVID? I wrote a thread a few months ago arguing: Yes. They are. This study just out in @NEJM provides a lot of important data https://t.co/v0GuQba3RZ1) Vaccines do provide higher and longer protection than you get from infection alone pic.twitter.com/7G48pJ9GrN— Vincent Rajkumar (@VincentRK) February 17, 2022

Original Article from The New England Journal of Medicine — Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

Since its emergence in Wuhan, China, covid-19 has spread and had a profound effect on the lives and health of people around the globe. As of 4 July 2021, more than 183 million confirmed cases of covid-19 had been recorded worldwide, and 3.97 million deaths. Recent evidence has shown that a range of persistent symptoms can remain long after the acute SARS-CoV-2 infection, and this condition is now coined long covid by recognized research institutes. Studies have shown that long covid can affect the whole spectrum of people with covid-19, from those with very mild acute disease to the most severe forms. Like acute covid-19, long covid can involve multiple organs and can affect many systems including, but not limited to, the respiratory, cardiovascular, neurological, gastrointestinal, and musculoskeletal systems. The symptoms of long covid include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain, concentration problems, and headache. This review summarizes studies of the long term effects of covid-19 in hospitalized and non-hospitalized patients and describes the persistent symptoms they endure. Risk factors for acute covid-19 and long covid and possible therapeutic options are also discussed.

US investigators have recovered millions in cryptocurrency they say was paid in ransom to hackers whose attack prompted the shutdown of the key East Coast pipeline last month, the Justice Department announced Monday.

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Crick and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre

The SARS-CoV-2 B.1.617.2 Variant of Concern (VOC), first detected in India, is now dominant in the UK, having rapidly1 displaced the B.1.1.7 strain2 that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently licensed COVID-19 vaccines against B.1.617.2 is unknown; although it possesses 12 mutations in its spike protein relative to the wildtype SARS-CoV-2 first detected in Wuhan, China, in December, 2019, B.1.617.2 lacks mutations at amino acid positions 501 or 484 in its ACE2 receptor-binding domain, commonly associated with VOCs (appendix p 2) or escape from neutralising antibodies (NAbs).

Post-hospitalization long covid in the UKQuality of life is poor:50% have serious long covid symptoms at 7 months after release.25% are disabledWorse in womenhttps://t.co/MP88GPdARF pic.twitter.com/eFBJhLJ37n— Yaneer Bar-Yam (@yaneerbaryam) March 14, 2021

SARS-CoV-2 spread rapidly in the Brazilian Amazon and the attack rate there is an estimate of the final size of a largely unmitigated epidemic. We use a convenience sample of blood donors to show that by June, one month after the epidemic peak in Manaus, capital of Amazonas state, 44% of the population had detectable IgG antibodies. Correcting for cases without a detectable antibody response and antibody waning, we estimate a 66% attack rate in June, rising to 76% in October. This is higher than in São Paulo, in southeastern Brazil, where the estimated attack rate in October is 29%. These r...

Estimates for England, Wales, Northern Ireland and Scotland.

This Viewpoint compares the COVID-19 per capita overall and excess mortality rates in the US vs that of 18 OECD countries and the timing of any increases in excess mortality between February and September 2020.

Regularly updated information on COVID-19 reported in the EU/EEA and the UK.

Three Quarters of People with SARS-CoV-2 Infection are Asymptomatic: Analysis of English Household Survey Data

The degree of protective immunity conferred by infection with SARS-CoV-2 is currently unknown. As such, the possibility of reinfection with this virus is not w

The neuroscientist who advises Independent Sage on Covid-19 discusses the predictive power of his mathematical modelling

Coronaviruses are a family of RNA viruses that typically cause mild respiratory disease in humans. A novel coronavirus (COVID-19) was identified in Wuhan, China in December 2019.

This Viewpoint from physicians with the Italian National Institute of Health confirms a higher case-fatality rate from coronavirus disease 2019 (COVID-19) in Italy compared with China and explains possible reasons, including age, cause of death definitions, and testing strategy.